A Pharmacor Analyst Call from Decision Resources

To ensure that our emails get to your inbox, please add Decision_Resources_Inc.@mail.vresp.com to your email address book or safe senders list.

If this message does not display properly, please click here to launch your browser.

Vying for Market Share in Triple Negative Breast Cancer - Will BSI-201 be a Worthy Competitor to Avastin?

— A Pharmacor Analyst Call from Decision Resources

Based on our 2009 Pharmacor Breast Cancer report, Decision Resources is offering an exclusive Pharmacor analyst call entitled Vying for Market Share in Triple Negative Breast Cancer - Will BSI-201 be a Worthy Competitor to Avastin? Because this analyst call will feature report findings, it is ONLY available to purchasers of this report.

Please contact us to learn how you can purchase this report and attend the analyst call.

Inhibition of polyadenosine 5’-diphosphoribose polymerase (PARP) has emerged as a novel therapeutic strategy in DNA-repair-deficient tumors including triple negative (estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-negative) breast cancer. Sanofi-Aventis has recently begun a Phase III clinical trial of its PARP inhibitor, BSI-201, in metastatic triple negative breast cancer. If approved and launched, BSI-201 is expected to take considerable market share away from Roche/Chugai’s Avastin and could emerge as the market leader within this niche breast cancer setting.

In this 15-minute analyst call, Decision Resources Analyst Niamh Murphy, Ph.D., will answer the following questions:

What are the advantages of BSI-201 over currently available agents used to treat triple negative breast cancer?
If BSI-201 were to be approved for triple negative breast cancer, how will its introduction into the market impact the sales of Avastin?
What is Decision Resources’ sales forecast through 2018 in the world’s major pharmaceutical markets for BSI-201 in triple negative breast cancer?

Dr. Murphy will conduct a live Q & A session after the presentation.

Registration

Vying for Market Share in Triple Negative Breast Cancer - Will BSI-201 be a Worthy Competitor to Avastin?

December 9, 2009 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris).

To learn how you can purchase this Pharmacor report and attend the analyst call, please contact us using the information below.

In North America — Steve Silvestro at 781-296-2626 or ssilvestro@dresources.com

In Europe — Kaj van Langendonck at +32-2-357-06-14 or kvanlangendonck@decisionresources.be

In Japan — Makiko Yoshimoto at +81-3-5401-2615 or makiko@dresources.jp

Pharmacor Analyst Call Details

Date & Time
Wednesday, December 9, 2009
10 a.m. U.S. Eastern Time,
4 p.m. Central European Time

Duration
15 minutes

About the Speaker

Niamh Murphy, Ph.D.

Niamh Murphy, Ph.D.

Niamh Murphy, Ph.D., is a research analyst in the Decision Resources oncology group. Dr. Murphy obtained an honors degree in biotechnology and a Ph.D. on the molecular biology of cervical cancer from Trinity College in Ireland. She worked as a postdoctoral scientist for several years, during which time she was involved in several international translational breast cancer research projects. Most recently, she analyzed drug resistance and chromosomal instability in breast cancer. Dr. Murphy has authored numerous peer-reviewed papers and abstracts and has presented data at international cancer conferences.

Terms of Use | Privacy Policy | Contact Us | Careers

Decision Resources • 260 Charles Street • Waltham, MA 02453

Register to receive our latest offers. You are receiving this email because you have previously requested information from Decision Resources.

© 2009 Decision Resources, Inc. All rights reserved.